Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: A systematic review and meta-analysis

Archives of Internal Medicine

Volumn 168, Issue 12, 2008, Pages 1261-1269

  Akl, Elie A ^a   Terrenato, Irene ^b   Barba, Maddalena ^b   Sperati, Francesca ^b   Sempos, Elena V ^c   Muti, Paola ^b   Cook, Deborah J ^d   Schünemann, Holger J ^b,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; ANTICOAGULANT AGENT;

ABDOMINAL SURGERY; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEMATOMA; HUMAN; LUNG EMBOLISM; MEDLINE; META ANALYSIS; MORTALITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; COMPARATIVE STUDY; NEOPLASM; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PERIOPERATIVE CARE; THROMBOSIS;

EID: 46449106401     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.12.1261     Document Type: Review

References (47)

1. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg: is there a "high risk" group? Am J Surg. 1970;120(4): 527-530.
2. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78(1):126-132.
3. Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coagul Fibrinolysis. 1992; 3(4):451-460.
4. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78(5):285-291.
5. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343 (25):1846-1850.
6. Flordal PA, Berggvist D, Burmark US, Ljungstrom KG, Torngren S; Fragmin Multicentre Study Group. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. Eur J Surg. 1996;162(10): 783-789.
7. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):338S-400S.
8. Borly L, Wille-Jorgensen P, Rasmussen MS. Systematic review of thromboprophylaxis in colorectal surgery: an update. Colorectal Dis. 2005; 7(2):122-127.
9. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88 (7):913-930.
10. Wong SS, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc. 2006;94(4):451-455.
11. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication bias and other biases. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. London, England: BMJ Books; 2001:189-210.
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ. 2003;327(7414):557-560.
13. Onarheim H, Lund T, Heimdal A, Arnesjo B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. Acta Chir Scand. 1986;152:593-596.
14. Baykal C, Al A, Demirtas E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001;22(2):127-130.
15. Boncinelli S, Marsili M, Lorenzi P, et al. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Minerva Anestesiol. 2001;67(10):693-703.
16. Dahan M, Boneu B, Renella J, et al. Prevention of deep venous thromboses in cancer thoracic surgery with a low-molecular-weight heparin, Fraxiparine: a comparative randomized trial. In: Bounameaux H, Samama M, ten Cate JW, eds. Fraxiparine: Second International Symposium: Recent Pharmacological and Clinical Data. New York, NY: John Wiley & Sons Inc; 1990:27-31.
17. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84(8):1099-1103.
18. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988;18(6):561-567.
19. Gallus A, Cade J, Ockelford P, et al. Orgaran (Org-10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease: a double-blind, randomised, multicentre comparison. Thromb Haemost. 1993;70(4): 562-567.
20. Godwin JE, Comp P, Davidson B, Rossi M. Comparison of the efficacy and safety of subcutaneous rd heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic-surgery for cancer [abstract]. Thromb Haemost. 1993;69(6):647.
21. Heilmann L, Tempelhoff GFV, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow-up. Clin Appl Thromb Hemost. 1998;4(4):268-273.
22. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77(3): 456-461.
23. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000; 16(4):815-824.
24. Bergqvist D, Burmark US, Frisell J, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost. 1990;16(suppl) :19-24.
25. European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1988;75(11): 1058-1063.
26. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg. 2001; 233(3):438-444.
27. Bergqvist D, Burmark US, Frisell J, et al. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis. 1986;16(suppl 2):11-18.
28. Bergqvist D, Matzsch T, Burmark US, et al. Low-molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis [published correction appears in Br J Surg. 1988;75(11):1077]. Br J Surg. 1988;75(9):888-891.
29. Boneu B. An international multicentre study: Clivarin (R) in the prevention of venous thromboembolism in patients undergoing general surgery: report of the International Clivarin (R) Assessment Group. Blood Coagul Fibrinolysis. 1993;4(suppl 1):S21-S22.
30. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand. 1988;67(2):99-103.
31. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs unfractionated heparin in gynecological surgery, II: reduced dose of low molecular weight heparin. Acta Obstet Gynecol Scand. 1992;71 (6):471-475.
32. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg. 1985;72(10): 786-791.
33. Kakkar VV, Stringer MD, Hedges AR, et al. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. Am J Surg. 1989;157(4):413-418.
34. Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP; H.B.P.M. Research Group. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg. 1991;78(4):412-416.
35. Limmer J, Ellbruck D, Muller H, et al. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis. Clin Investig. 1994;72(11):913-919.
36. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 2003; 59(5):363-372.
37. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988;75(2):128-131.
38. Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Aust N Z J Obstet Gynaecol. 1998;38 (1):91-92.
39. Oxman A, Guyatt G. When to believe a subgroup analysis. In: Guyatt G, Rennie D, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Press; 2002:553-565.
40. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326 (7387):472.
41. Gondret R, Dominici L, Angelard B, et al. Safety of preoperative enoxaparin in head and neck cancer surgery. Head Neck. 1995;17(1):1-6.
42. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol. 2007;105(3):813-819.
43. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715.
44. Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest. 2007;132(4):1131-1139.
45. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev. 2007;(3):CD006652.
46. Akl EA, Kamath G, Kim SY, et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev. 2007; (2):CD006466.
47. Andtbacka RH, Babiera G, Singletary SE, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006;243(1):96-101.